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ABSTRACT
A sad little story about a maimed Martian astronaut is used to illustrate a
method of improving confidence interval calculations. Confidence intervals in
medical statistics are currently calculated from the data available in a clinical
trial or meta-analysis considered in isolation from all other information available
on earth. Likewise, the Martian in the story uses only information available to her,
in isolation from further information from earth. However there is further objective
knowledge available to people on earth to improve the Martian’s estimate. In the
same way we have objective prior knowledge available to us outside of the current
clinical trial results which we can use to improve confidence interval calculations.
This prior knowledge is incorporated into the confidence interval calculations using
Bayesian methods. The objective prior knowledge that is available is the fact that
there were researchers who felt it worthwhile to conduct the trial and journal
editors who felt it worthwhile publishing the results. It is shown here that the use
of this information contracts the width of the log confidence interval by a factor
of about 3/4 on average. Unlike standard confidence intervals, these new intervals
also have the advantage of being directly interpretable in terms of probabilities.
These probabilities also enable calculation of improved point estimates.
These calculations are applied to 100 randomly selected Cochrane systematic
reviews, and show serious problems in assessing medical treatments. For treatments
not involving new drugs or devices, it is shown that there is evidence of a bias
towards a negative assessment. The calculations here make a quantitative adjustment
for publication bias. They show that the proportion of negative assessments do
not reflect an appropriate adjustment for publication bias.
INTRODUCTION
This paper extends a recent approach [1] to the analysis of clinical trial statistics,
to give credible intervals. These improve the assessment of a specific clinical
trial statistic by factoring in experience with clinical trial statistics from across
the Cochrane Collaboration [2]. These credible intervals have a similar role to
confidence intervals, but have several advantages – they are usually narrower,
unlike confidence intervals they can be directly interpreted as giving probabilities
and they automatically allow for publication bias. Software to calculate them is
being made freely available. Credible intervals are calculated for 100 randomly
selected studies from the Cochrane reviews. The results suggest that Cochrane
tends to have a bias against finding a reasonable possibility of benefit.
In this paper, reviews of new drugs and new medical devices are excluded and
the paper focusses on other treatments. This exclusion is motivated by concern
2
that publication bias may be unpredictably large where there are commercial
pressures [3-6] and recognition that a conservative approach by Cochrane here,
may be appropriate to allow for unexpected dangerous side effects.
To explain the idea behind the method, consider a quirky but sad tale of the
first astronaut to come from Mars. The astronaut has the misfortune to arrive on
earth in the dark and lands next to a man who is a violent anti-alien extremist.
She is blinded in an attack by the extremist but is then rescued and taken to the
police to give a statement about her attacker. The astronaut is aware of the metric
system but she has no conception about the height of a typical human. She tells
the police that given it was dark and that she got just a glimpse of her attacker,
she is unsure of his height, she thinks he was around 200cm and is 95% confident
that he was somewhere in the range 170cm to 230cm. The police however know
the distribution of human male heights in their country and know that 95% are
between 150cm and 190cm and virtually no-one is anywhere near 230cm. It is
therefore reasonable for them to believe that it is far more likely that the attacker
has a height somewhere around the lower half of the 170 to 230 range. In fact
the police do better and as explained in Appendix 1, they do a calculation using
Bayes’ theorem, to find that with the information available, there is a 95% chance
that the attacker’s height is in the range 163cm to 196cm. The calculation results
in the width of the interval giving the likely height of the attacker being contracted
from 60cm to 33cm. Equations (1) and (2) of Appendix 1 show that regardless of
the accuracy of the Martian’s estimate and regardless of the variability of human
height, there will always be at least some contraction of the width of the confidence
interval. It will also be shifted towards a plausible range according to a weighted
average of the Martian’s guess and the average human height with the weights
being determined by the uncertainty in the Martian’s guess and the variability in
human height.
The situation with clinical trials and meta-analyses is similar in a sense to the
situation of the Martian. If we stop our analysis after calculating a confidence
interval we are using no more information about our treatment than the Martian
used about her attacker’s height. However, we can improve the situation by using
the sort of calculations done by the police who rescued the Martian and factor
in objective background knowledge. Objective background knowledge is available
- if we look at all the clinical trials and meta-analyses that have ever been done
and recorded in the Cochrane Collaboration [2], there is a particular pattern or
distribution for effectiveness, just as there is a particular distribution for human
heights. In effect, we use the objective background knowledge that we are looking
at the results of a clinical trial of a treatment where there was sufficient reason to
trial that treatment in the first place.
Improving uncertain effectiveness estimates using the distribution of effectiveness
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is a bit more complicated than improving uncertain height estimates using the
distribution of heights, for several reasons:
• The distribution of human heights is available from a large number of quite
accurate measurements of human height whereas the distribution of effectiveness
is available only from a limited sample of uncertain measurements [1].
• The distribution of human heights follows a normal distribution quite closely,
whereas the distribution of effectiveness is not as straightforward.
• In compiling the distribution of human heights there was no tendency to
systematically exclude dwarves from the sample, whereas it can be assumed
that there was a degree of publication bias operating to exclude “non-significant”
measures of effectiveness from publication.
However, allowance can be made for these complications and an effectivenss
distribution can be obtained. Effectiveness can be measured in several different
ways. Some measures related to effectiveness are dependent on the unit of measurement
(eg. kilograms weight loss versus pounds weight loss) or may reflect the size of the
study as well as the effectiveness (eg. the p-value). A measure of effectiveness free
of these problems, is readily available when dealing with dichotomous outcomes
such as live or die and when these outcomes are summarised by statistics such as
relative risks, relative hazards or odds ratios. For convenience we abuse language
and use the term “relative risk” or RR in what follows to refer to all such statistics.
With such statistics, a relative risk of 1.00 signifies zero effectiveness. Since
log(1.00) is zero, this suggests a choice of log relative risk as the effectiveness
measure. This choice of effectiveness measure is also convenient because conventional
confidence interval calculation of relative risk assumes a normal distribution after
a log transformation [7].
The relative risks used here have to satisfy certain criteria [1]. Relative risks are
eligible if they come from trials or meta-analyses in which there is a comparison
of a standard treatment with the same standard treatment plus an additional
treatment. The rationale is that such a trial would not take place unless there was a
general sentiment that the additional treatment might be of benefit and is unlikely
to be harmful, whereas this would not apply in the less common situation where
two mutually exclusive treatments are compared – such as two competing surgical
approaches. Presumably, for eligible trials, the general sentiment will be partly
reflected in reality. Treatments will often have at least some modest effectiveness,
a few might be remarkably effective but some will be entirely useless with zero
effectiveness and perhaps a few will be counterproductive. These ideas were
embodied in a mathematical model which allocated a proportion to have precisely
zero effectiveness with the remainder having an effectiveness chosen from a normal
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distribution centred on a positive number. Data in the form of 101 effectiveness
measures previously obtained from Cochrane [1] were used to calculate the three
parameters of the model. One parameter gives the proportion of treatments
that have zero effectiveness and the other two describe the normal distribution
of effectiveness for the remaining treatments. The parameter estimates were made
by curve fitting as explained elsewhere [1]. Allowance was then made for the
uncertainty about the three estimated parameters by a bootstrapping method
described in the appendix. Importantly, the method also makes allowance for a
publication bias against non-significant results by a factor of 2.78 [8]. The outcome
is a probability distribution of effectiveness of diverse treatments across all medical
problems as shown in Figure 1.
This distribution can then be used in a similar way to the police use of the
distribution of diverse heights of all men to improve the Martian’s estimate. The
mathematics here is given in the Appendix. The idea behind the mathematics can
be loosely explained in words using as an example, a trial which yields a relative
risk of 2.83 with a 95% confidence interval of (2.00, 4.00). We might ask, “What is
the probability that the true relative risk is around 2.00?”. From the definition of
a 95% confidence interval, we know that if the true value was either 2.00 or 4.00 we
would, in each case, have a probability of 2.5% of getting a relative risk of around
2.83 (actually 2.83 or beyond). Referring to Figure 1 shows that across Cochrane
we estimate relative risks around 2.00 to be about 20 times (≈ 0.406/0.0206) more
common than values around 4.00 . Combining this with the fact that in this clinical
trial, values of both 2.00 and 4.00 are equally capable of giving the observed value
of 2.83, tells us that a relative risk for this treatment of around 2.00 is about 20
times more likely than a value around 4.00. Taking into account the log scale and
using the mathematics in the appendices and elsewhere [1, 9] makes these ideas
more precise and extends them a little to give the probability of any value for the
true effectiveness. This allows calculation of a credible interval that has a 95%
chance of containing the value of the true amount of effectiveness. Free software
is made available to implement these calculations. (It is intended that this will
become available on Research Data Australia https://researchdata.ands.org.au/)
In the example here, the calculations show that there is a 95% probability that
the true relative risk in this trial is in the range (1.48, 3.41). The expected relative
risk ( E(RR) ) is also calculated as described in the appendix. This is a probability
weighted average of the likely effectiveness of a treatment. The expected relative
risk is a modification of the relative risk which takes account of the background
distribution of effectiveness and makes appropriate adjustment to compensate for
the log transformation. In this example the E(RR) is 2.35. The calculations also
tell us that, to two decimal places, the probability that the treatment is either
counterproductive or ineffective is, in both cases, zero.
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Figure 1. Prior Distribution
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Figure 1: This gives the distribution of effectiveness as measured by the log of the
relative risk. It shows the function given as equation (5) in the appendix. Dotted
lines on the graph show the coordinates of two points:- the height of the graph at a
log relative risk of ln(4) (the natural log of 4) is 0.0202 and the height of the graph
at a log relative risk of ln(2) is about 20 times larger at 0.406. This tells us that
across Cochrane, log relative risks around ln(2), are about 20 times more common
than log relative risks around ln(4). On a scale of relative risks themselves, this
translates into relative risks around 2 being about 40 times more common than
relative risks around 4.
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METHODS
A further 100 relative risks with their confidence intervals from trials and meta-analyses
throughout Cochrane were selected using a random number generator and the
protocol described previously [1]. As well, for each study selected, the review
abstract was read and a ranking was given regarding the treatment. A rank of
1 or 2 was assigned if the reviewers thought that the treatment was definitely or
probably of zero effectiveness (or counterproductive). A ranking of 3 was assigned
if the review abstract indicated that there remained complete uncertainty about
the effectiveness of the treatment and a rank of 4 or 5 was assigned if the review
indicated that the treatment was probably or definitely effective.
For the effectiveness distribution to be defined, it is necessary that an anticipated
effect is consistently reflected by the numerical measure of effectiveness. However, a
relative risk bigger than 1 may be associated with a beneficial effect as for example
in terms of a higher “risk” of giving up smoking with an anti-smoking treatment, or
with a harmful effect as in a higher risk of dying with the additional treatment. For
consistency, the algorithm described here must be given information about whether
the direction of effect tends in an anticipated or opposite direction. Internally the
algorithm stores all relative risks in favour of the extra treatment as a relative risk
bigger than 1. In effect a relative risk of dying with the additional treatment of 0.5,
is translated into a relative risk of 2.0 of dying if given just the standard treatment.
The figures display results using this approach. However, for consistency with the
original confidence intervals, Table 2 displays results as though there had been no
inversion.
Occasionally, there is an additional twist here. Sometimes researchers are
hoping for a negative answer to the question “Is standard treatment plus the
additional treatment better than standard treatment alone?”. For example, to
reduce costs, researchers may hope to show that less highly trained staff can
perform a procedure as well as more highly trained staff. Here one would regard
“standard treatment plus the additional treatment” as the procedure being performed
by someone with baseline training plus extra training and “standard treatment”
as the procedure being performed by someone with baseline training alone. The
researchers may be hoping to find “no difference” between the two arms of the
trial, but the outcome that could be anticipated is that, if there is any effect, it
will be that the extra training makes a beneficial difference - something that would
be a disappointing result for the those conducting the trial.
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RESULTS
A total of 340 Cochrane reviews were searched to give 100 relative risks. None were
significantly counterproductive, 16 showed a non-significant negative effect, in 3
cases the effect size was precisely zero, 29 showed a non-significantly positive effect
and 52 showed a significantly positive effect. This outcome is consistent (χ28 = 9.31,
p-value = 0.32) with the outcome found when 100 and then 101 relative risks were
collected from Cochrane in two previous studies [1, 9]. The 100 reviews with the
relative risk used, are numbered and are listed in Table 1.
The effectiveness assessment rankings 1, 2, 3, 4, 5 (that is, from certainly
ineffective or counterproductive to certainly effective) were appropriate to 6, 7, 28,
31 and 28 Cochrane reviews respectively. It is of interest that of the reviews with
the rank of 1 there was no negative RR result and 5 positive RR results, for rank 2
the figures were 2 and 4, for rank 3 the figures were 11 and 17, for rank 4 the figures
were 2 and 28 and for the most positive effectiveness ranking of 5 the figures were
1 and 27. All studies except for one ranked 3 (uncertain) had a positive E(RR),
that is, an expected effect in the direction anticipated. The results are displayed
in Figure 2.
The remaining information from the analysis is displayed in Table 2. For each
study numbered in Table 1, Table 2 gives the original confidence interval for RR,
together with the probabilities of counterproductive, zero or positive effect, the
95% credible interval, the E(RR) and the effectiveness ranking. In all cases with
a low ranking of 1 or 2 (definitely or probably useless or counterproductive), the
probability of a positive effect is more than 27% and in all cases exceeds the
probability of a counterproductive effect by at least 18%.
On average, the width of the 95% credible intervals is about 3
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that of the
original 95% confidence interval on the log scale (95% confidence interval for this
value of 0.75 is (0.70, 0.81)).
DISCUSSION
It is to be expected that there will be an imperfect correlation between the
RR or the E(RR) and the Cochrane assessment of effectiveness as summarised
by the ranking used here. Unlike the E(RR) which intrinsically takes account
of publication bias, Cochrane systematic reviews only occasionally take formal
account of publication bias by presenting funnel plots. However, the E(RR)
calculation relies only on the first statistic cited in a Cochrane review, whereas the
review itself may take account of a number of analyses which may be evaluating
a variety of different endpoints and the review will also judge the quality of the
clinical trials. Cochrane reviews also occasionally take some account of observational
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Figure 2: This gives some of the information of Table 2 in diagrammatic form. The
100 randomly chosen studies are grouped according to the Cochrane reviewers’
assessment of their likely effectiveness. Above each effectiveness ranking from 1
to 5, the first relative risk mentioned in each of the 100 studies is plotted. The
simple relative risk is displayed slightly to the left and the expected relative risk is
displayed slightly to the right. The points are marked by small font numbers which
refer to the study numbers given in Tables 1 and 2. Due to display limitations
perhaps only the more unusual study numbers will be entirely legible.
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studies and non-randomised trials and may make a somewhat subjective judgement
about whether an outcome is clinically significant as well as statistically significant.
Nevertheless there is a disturbing discordance in the results between the effectiveness
ranking on the one hand and the RR and even moreso, the E(RR) on the other.
In particular, the results show that in terms of conventional RR’s, E(RR)’s and
probabilities, all 13 treatments ranked as definitely useless or counterproductive,
deserved a higher ranking. It could be reasonable for many treatments with
weakly positive RRs or E(RR)s to be ranked as inconclusive, perhaps because
they were underpowered relative to the effect size or the trial had design faults,
but a conclusion stating that the results show the treatment effects are probably
or convincingly negative, seems wrong. It is possible to explain this discordance
by arguing that my rankings are inappropriate, or the effect size is convincingly
too small to be worthwhile, or that bias in a clinical trial was so large that one
would anticipate a negative result from an unbiased study, or that second or
subsequent statistics in a review gave a convincingly negative impression. However,
perusal of the negatively ranked reviews do not support such arguments (except
perhaps for review 74). Instead, it seems almost certain that the negative reviews
in the context of mostly positive RRs represent an undue conservatism by the
reviewers. Presumably, this conservatism reflects concern about publication bias.
A significant finding of this paper is that this concern is misguided. As explained
above, the E(RR)s make appropriate allowance for publication bias, and all the
E(RR)s of the negatively ranked reviews are in fact positive.
The Cochrane reviews give much more weight to statistical evidence from
randomised clinical trials than to prior evidence based on mechanism. It is argued
that the strong emphasis on statistical evidence promotes objectivity. However, the
wisdom of this approach, is questioned by some philosophers of science, Bayesian
statisticians and some medical researchers [10, 11]. This paper shows that many
negative Cochrane reviews are probably wrong. The opposite problem of undue
enthusiasm for treatments has received more attention [12, 13]. However, this
paper using a limited amount of additional but objective prior information shows
the problem of false negativity may be as important. If using objective prior
probabilities of effectiveness, shows that Cochrane not infrequently draws wrong
conclusions, then there is a case for incorporation of more prior knowledge. In
particular, assessment of the effectiveness of treatments in medicine may be improved
by dropping a rigid adherence to the criterion of objectivity which prevents the
cautious use of knowledge of mechanism and expert opinion as a component of
prior probability.
Competing interests and acknowledgements: no competing interests; I thank
anonymous reviewers for their helpful comments.
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Appendix 1 - The police deduction from the uncertain
Martian observation
We assume that the Martian’s observation has two components X, an unknown
value from the range of values of adult male human heights and Y, an unknown
value from the range of errors that could be made by the Martian. The calculation
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assumes that the range of errors is normally distributed, centred on zero and the
gap between 170 and 230 represents 2 × 1.96 standard deviations. The standard
deviation of the errors in the Martian’s observation is therefore 230−170
2×1.96 = 15.3
In symbols then we have Y ∼ N(0, s2) = N(0, 15.32). We will assume that the
size of the error that could be made by the Martian will be independent of the
assailant’s actual height. We will also assume that the police know that in their
country, the distribution of human male heights is given by X ∼ N(µ, σ2) =
N(170, 10.22) so that 95% are between 150cm and 190cm. The outcome that the
Martian could possibly observe, is U = X + Y. As the sum of two independent
normal variables U = X + Y ∼ N(µ, σ2 + s2) = N(170, 15.32 + 10.22). We want
to find the probability distribution of the height of the man X given knowledge
of the observation U. We denote this probability distribution as fX|U =
fX,U
fU
. To
find fX,U we note that fX,U = fX,Y|J| where J is the Jacobian = 1. We also note
that by independence fX,Y = fXfY = fX(x)fY(u− x). We then have:-
fX|U =
1√
2piσ
e
−1
2
(x−µ
σ
)
2
1√
2pis
e
−1
2
(u−x
s
)
2
1√
2pi(σ2+s2)
e
−1
2
(
u−µ√
σ2+s2
)2
After some algebra we find that fX|U ∼ N(µX|U, σ2X|U) where
σX|U =
√
σ2s2
σ2 + s2
(1)
and
µX|U =
µs2 + uσ2
σ2 + s2
(2)
Using the values of µ, σ and s given above, and taking the point estimate of u to
be 200cm, we have µX|U = 179.2cm and σX|U = 8.5cm. The 95% credible interval
µX|U ± 1.96σX|U is then (162.6cm,195.9cm).
It is relevant to note that (1) can be written as:
σX|U = σ
√
s2
σ2+s2
= s
√
σ2
σ2+s2
< min(σ, s) so the 95% credible interval must be
smaller than the original 95% confidence interval
and that (2) can be written as:
µX|U = s
2
σ2+s2
µ + σ
2
σ2+s2
u = wxµx + wyu where wx + wy = 1 So µX|U is a weighted
average of µ and the observation u with the weights being proportional to the
precision (ie. inverse variance) of X and of Y
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Appendix 2 - Extension of the method to credible
intervals for clinical trials
We assume that the uncertainty about the true value of effectiveness of a treatment
is an amount that is normally distributed, when effectiveness is measured as the
log of the relative risk [7]. As in Appendix 1 we use the symbol Y for a value from
this distribution, with the standard deviation s, determined by the width of the
confidence interval of the log relative risk so that as previously Y ∼ N(0, s2). We
use the symbol X for a value from the distribution of values of the true effectiveness
of a treatment. This distribution is described below. For both the Martian’s
estimate of height and for the clinical trial’s estimate of effectiveness, U represents
the outcome that may be observed. As in Appendix 1, U = X + Y and our task
involves finding fX|U.
In the first instance, it is assumed that the distribution of X, comprises a
proportion at precisely zero effectiveness with the remainder chosen from a normal
distribution centred on a positive number, so
X ∼ fX(x) = pδ(x) + (1− p)φ(x, µ, σ2) (3)
where the pδ(x) term uses the Dirac delta function and represents a spike of
probability at zero of size p meaning that this proportion of treatments is precisely
useless and φ(x, µ, σ2) is used for the normal probability density function. There is
no convincing theoretical reason and only a modest amount of empirical evidence
to support this form for X . However, the method here may not be too sensitive to
the precise form of the effectiveness distribution [9] and in any case, as described
below, the distribution we eventually employ in the calculations allows greater
flexibility.
As in Appendix 1 we want fX|U =
fX,U
fU
and as before, the numerator fX,U =
fX(x)fY(u− x). The numerator fX,U is then
fX,U(x, u) = pφ(u− x, 0, s2)× δ(x) + (1− p)× φ(x, µ, σ2)× φ(u− x, 0, s2)
= pφ(u, 0, s2)× δ(x) + (1− p)× φ(x, µ, σ2)× φ(u− x, 0, s2)
Now, with some algebra it can be shown that the terms on the right side of the
line above satisfy
φ(x, µ, σ2)× φ(u− x, 0, s2) = φ(u, µ, σ2 + s2)× φ(x, µ∗, σ2∗)
where µ∗ =
s2µ+σ2u
σ2+s2
and σ∗ = σs√σ2+s2 so we have
fX,U(x, u) = pφ(u, 0, s
2)× δ(x) + (1− p)× φ(u, µ, σ2 + s2)× φ(x, µ∗, σ2∗)
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We then have
fU(u) =
∫ ∞
−∞
fX,U(x, u)dx
= pφ(u, 0, s2) + (1− p)× φ(u, µ, σ2 + s2)
We now obtain
fX|U(x|u) = fX,U
fU
=
pφ(u, 0, s2)× δ(x) + (1− p)× φ(u, µ, σ2 + s2)× φ(x, µ∗, σ2∗)
fU(u)
= p∗(u)δ(x) + (1− p∗(u))φ(x, µ∗, σ2∗) (4)
where
p∗ = p∗(u) =
pφ(u, 0, s2)
fU(u)
Hence the distribution of fX|U(x|u) given in (4), like the distribution of fX(x)
itself given in (3), is a mixture distribution of a spike at zero and a normal, but
with parameters that depend via the definitions of µ∗ and σ∗ on u and s as well
as on the parameters p, µ, σ of the original fX(x) distribution. Inspection of the
expressions for µ∗ and σ∗ show that they are identical in form to equation (2)
and (1) respectively, and so contraction of the confidence interval and a weighted
shift of the mean would be expected to apply here. This density function would
also be the key to defining an interval containing 95% of the probability of X in
fX|U(x|u), if we were certain about the parameters p, µ and σ. However, unlike
the police in Appendix 1, who have virtually certain knowledge of the parameters
of the normal distribution describing the height of humans based on measuring
thousands of humans with an accurate ruler, we have only uncertain knowledge
of the distribution of effectiveness based on fitting a curve to a sample of 101
relative risks [1]. Furthermore, those 101 relative risks in Cochrane were themselves
not measured with an accurate “ruler”, but were measured with a blurring of
uncertainty described by the confidence interval for each item of data.
To allow for this uncertainty and to allow for publication bias, appropriately
counter-biased bootstrapping was performed. In particular the estimation of p, µ
and σ obtained by curve fitting, was repeated with different sets of 101 relative
risks. Each of these sets of 101 relative risks were obtained by resampling with
replacement from the observed set of 101 relative risks. However, this resampling
was adjusted to over-represent the non-significant results by a factor of 2.78 to
counteract publication bias [8]. This process gives 1000 sets of the three parameters
p, µ and σ. We then index these parameters by (i) so we have a 1000 sets
{p(i), µ(i), σ(i)} and correspondingly we have a 1000 functions f (i)X (x) Our knowledge
of fX(x) is defined to be a sort of average of all the f
(i)
X (x), or more precisely, a
14
mixture distribution in which any component has a 1
1000
probability of being chosen.
Denoting this “average” by f
(a)
X (x) we have
f
(a)
X (x) =
1
1000
1000∑
i=1
(
p(i)δ(x) + (1− p(i))φ(x, µ(i), σ(i)2
)
= p(a)δ(x) +
1
1000
1000∑
i=1
(
(1− p(i))φ(x, µ(i), σ(i)2)
)
(5)
where p(a) is the average of the p(i). The shape of this prior distribution fX is
shown in Figure 1 in the main text.
Noting the similarity between (3) and (4) we likewise have
f
(a)
X|U(x|u) =
1
1000
1000∑
i=1
(
p(i)∗ δ(x) + (1− p(i)∗ )φ(x, µ(i)∗ , σ(i)2∗
)
= p(a)∗ δ(x) + (1− p(a)∗ )
1
1000
1000∑
i=1
( (1− p(i)∗ )
(1− p(a)∗ )
φ(x, µ(i)∗ , σ
(i)2
∗ )
)
(6)
where p
(a)
∗ is the average of the p
(i)
∗
We see that f
(a)
X|U(x|u) retains a simple spike at zero. However the other
component is not as neat. It is a mixture distribution of normals and generally will
not be accurately approximated by a single normal nor will it even be symmetric.
It will be convenient to write the probability density function of this mixture
distribution of normals as β(x, {pui , µui , σui}) to give the form of fX|U(x|u) we
require for use in what follows:
f
(a)
X|U(x|u) = p(a)∗ δ(x) + (1− p(a)∗ )β(x, {p(i)∗ , µ(i)∗ , σ(i)∗ })
With this probability density function for the amount of true effectiveness X
given an observation of a particular value of effectiveness u of U together with
the measurement of uncertainty of this observation s, it is now straightforward to
develop an algorithm to find the shortest interval in the distribution of X that
contains 95% of the probability - the 95% credible interval. However, we note that
the added complexity of the problem here means that although there are equations
involved similar to (1) and (2), the contraction of the distribution and the shift of
its centre, are not straightforward.
In the algorithm to define the 95% credible interval, there are three main
cases. If p
(a)
∗ > 0.95 the credible interval is of length zero and located at zero.
If 0.05 < p
(a)
∗ < 0.95 the credible interval must contain the spike at zero, but
there are three sub-options. The spike can be internal in the credible interval or
on left or right boundary (the spike at zero on the right boundary of the interval
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though would likely only arise when the treatment was quite counterproductive).
If p
(a)
∗ < 0.05 there is the additional sub-option that the credible interval may
not include the spike at zero - this spike will be very small when a convincing
result is obtained. To decide on which of these sub-options might apply we
use a search procedure to find the shortest interval (xl1 , xu1) such that (1 −
p
(a)
∗ )
∫ xu1
xl1
β(x, {p(i)∗ , µ(i)∗ , σ(i)∗ })dx = 0.95 and the shortest interval (xl2 , xu2) such
that (1−p(a)∗ )
∫ xu2
xl2
β(x, {p(i)∗ , µ(i)∗ , σ(i)∗ })dx = 0.95−p(a)∗ . We refer to these intervals
as interval 1 and interval 2 respectively. Some thought shows that if both these
intervals contain the spike at zero, we have an internal spike and interval 2 is the
credible interval. If neither contain the spike, interval 1 is the credible interval.
If interval 1 contains the spike, but interval 2 doesn’t, then the spike is on a
boundary and (after a check to identify which boundary - usually the left - assumed
in what follows) a search procedure is performed to find xu3 such that (1 −
p
(a)
∗ )
∫ xu3
0
β(x, {p(i)∗ , µ(i)∗ , σ(i)∗ })dx = 0.95−p(a)∗ . The credible interval is then [0, xu3).
To calculate the expected relative risk, E(RR) we multiply equation (3) by ex
and integrate to give∫ ∞
−∞
exf
(a)
X|U(x|u)dx =
∫ ∞
−∞
ex
1
1000
1000∑
i=1
(
p(i)∗ δ(x) + (1− p(i)∗ )φ(x, µ(i)∗ , σ(i)2)∗ )
)
dx
= p(a)∗ +
1
1000
1000∑
i=1
(1− p(i)∗ )
∫ ∞
−∞
exφ(x, µ(i)∗ , σ
(i)2
∗ )dx
= p(a)∗ +
1
1000
1000∑
i=1
(1− p(i)∗ )
(
eµ
(i)
∗ + 12σ
(i)2
∗
)
(7)
The work described here could be improved by using further data for calibration
and perhaps calibration for particular branches of medicine and for new drugs
where the data emerge from pre-registered trials. Calibration could also be specialised
to particular types of statistics with perhaps adjustment for the approximations
used in confidence interval calculations. Continuous data could be used if, instead
of the p-value, effect size was measured in comparison to the size of the background
variability. Whilst an effect of fitting one alternative model was explored elsewhere
[9], much more extensive testing of the sensitivity of the results to the model used
for prior distribution is also desirable. However, all this is beyond the scope of this
paper.
The program to code for the calculations will be made available on James Cook
University’s Tropical Data Hub and then on Research Data Australia https://researchdata.ands.org.au/
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Table 1. Numbered List of Cochrane Studies Used as Data
Study Study Title Statistic Used
Number (truncated if necessary at around 90 characters) and effect direction
1 Routine pre-pregnancy health promotion for
improving pregnancy outcomes
RR 1.24 (1.06, 1.44) +ve
2 Routine surgery in addition to chemotherapy for
treating spinal tuberculosis
OR 0.88 (0.36, 2.16) +ve
3 Home-based versus centre-based cardiac
rehabilitation
RR 0.79 (0.43, 1.47) +ve
4 Interventions for pain with intrauterine device
insertion
OR 0.02 (0.01, 0.09) +ve
5 Oral immunoglobulin for preventing necrotizing
enterocolitis in preterm and low birth weight
RR 0.84 (0.57, 1.25) +ve
6 Topical capsaicin (low concentration) for chronic
neuropathic pain in adults
RR 2.04 (0.75, 5.54) +ve
7 Day hospital versus outpatient care for people
with schizophrenia
RR 0.71 (0.56, 0.89) +ve
8 Steroids for improving recovery following
tonsillectomy in children
RR 0.49 (0.41, 0.58) +ve
9 Decompressive surgery for treating nerve
damage in leprosy
RR 1.13 (0.10, 1.77) +ve
10 On-site mental health workers delivering
psychological therapy and psychosocial
interventions
RR 0.67 (0.56, 0.79) +ve
11 Enteral nutrition for maintenance of remission
in Crohn’s disease
OR 0.30 (0.09, 0.94) +ve
12 Dietary calcium supplementation for preventing
colorectal cancer and adenomatous polyps
OR 0.74 (0.58, 0.95) +ve
13 Low molecular weight heparin for prevention of
microvascular occlusion in digital replantation
RR 1.03 (0.87, 1.22) -ve
14 Intercessory prayer for the alleviation of ill
health
RR 1.00 (0.74, 1.36) +/-
15 Alpha-2 adrenergic agonists for the prevention
of cardiac complications among patients
undergoing surgery
RR 0.66 (0.44, 0.98) +ve
16 Interventions for prevention of post-operative
recurrence of Crohn’s disease
RR 0.23 (0.09, 0.57) +ve
17 Open Mesh versus non-Mesh for groin hernia
repair
OR 0.37 (0.26, 0.51) +ve
Continued on next page
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Table 1 – continued from previous page
Study Study Title Statistic Used
Number and effect direction
18 Pelvic floor muscle training for prevention and
treatment of urinary and faecal incontinence in
antenatal
RR 0.74 (0.58, 0.94) +ve
19 Chest shielding for prevention of a
haemodynamically symptomatic patent ductus
arteriosus in preterm
RR 0.23 (0.05, 1.01) +ve
20 Antithrombotic therapy for improving maternal
or infant health outcomes in women considered
at risk
RR 0.40 (0.20, 0.78) +ve
21 Methotrexate for ankylosing spondylitis RR 3.18 (1.03, 9.79) +ve
22 External cephalic version for breech
presentation before term
RR 1.04 (0.64, 1.69) -ve
23 Early versus late initiation of epidural analgesia
for labour
RR 1.02 (0.96, 1.08) +ve
24 Corticosteroids for the resolution of malignant
bowel obstruction in advanced gynaecological
OR 0.51 (0.21,1.23) +ve
25 Antibiotic regimens for suspected early neonatal
sepsis
RR 0.75 (0.19, 2.90) -ve
26 Patient education in the management of
coronary heart disease
RR 0.79 (0.55,1.13) +ve
27 Cotrimoxazole prophylaxis for opportunistic
infections in adults with HIV
RR 0.69 (0.55, 0.87) +ve
28 Erythromycin for the prevention of chronic lung
disease in intubated preterm infants
RR 1.40 (0.72, 2.70) -ve
29 Vitamin D supplementation in pregnancy RR 0.52 (0.25,1.05) +ve
30 Thrombelastography (TEG) or
thromboelastometry (ROTEM) to monitor
haemotherapy versus usual care
RR 0.77 (0.35,1.72) +ve
31 Unit-dose packaged drugs for treating malaria RR 1.18 (1.12,1.25) +ve
32 Therapy-based rehabilitation services for
patients living at home more than one year
after stroke
RR 0.85 (0.22, 3.26) +ve
33 Lecithin for dementia and cognitive impairment OR 3.01 (0.92, 9.81) -ve
34 Antiviral treatment for preventing postherpetic
neuralgia
RR 0.75 (0.51, 1.11) +ve
35 Ethamsylate for the prevention of morbidity and
mortality in preterm
RR 0.63 (0.47, 0.86) +ve
36 Intensive glucose control versus conventional
glucose control for type 1 diabetes mellitus
RR 0.27 (0.18, 0.42) +ve
Continued on next page
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Table 1 – continued from previous page
Study Study Title Statistic Used
Number and effect direction
37 Palliative endobronchial brachytherapy for
non-small cell lung cancer
RR 1.57 (0.22, 11.08) -ve
38 Ursodeoxycholic acid for primary biliary
cirrhosis
RR 0.97 (0.67, 1.42) +ve
39 Non-steroidal anti-inflammatory drugs
(NSAIDs) for treating lateral elbow pain
in adults
RR 1.49 (1.04, 2.14) +ve
40 Transfusion thresholds and other strategies for
guiding allogeneic red blood cell transfusion
RR 0.77 (0.62, 0.95) +ve
41 Competitions and incentives for smoking
cessation
OR 1.42 (1.19, 1.69) +ve
42 Cranial irradiation for preventing brain
metastases of small cell lung cancer
RR 0.84 (0.73, 0.97) +ve
43 Stem cell treatment for acute myocardial
infarction
RR 0.93 (o.58, 1.50) +ve
44 Single layer versus double layer suture
anastomosis of the gastrointestinal tract
OR 0.76 (0.44,1.32) -ve
45 Interventions for tubal ectopic pregnancy OR 0.28 (0.09, 0.86) +ve
46 Intravitreal low molecular weight heparin and
5-Fluorouracil for the prevention of proliferative
RR 0.48 (0.25, 0.92) +ve
47 Amphetamines for improving recovery after
stroke
OR 1.45 (0.64, 3.27) -ve
48 Perineal techniques during the second stage of
labour for reducing perineal trauma
RR 0.48 (0.28, 0.84) +ve
49 Interventions for preventing delirium in older
people in institutional long-term care
RR 0.85 (0.18, 4.00) +ve
50 Interventions for treating sexual dysfunction in
patients with chronic kidney disease
RR 1.00 (0.08, 13.02) +/-
51 Bone morphogenetic protein (BMP) for fracture
healing in adults
RR 1.19 (0.99, 1.43) +ve
52 Loxapine for schizophrenia RR 0.30 (0.14, 0.63) +ve
53 Co-bedding in neonatal nursery for promoting
growth and neurodevelopment in stable preterm
twins
RR 0.85 (0.18, 4.05) +ve
54 Zinc supplements for preventing otitis media R1 0.69 (0.61, 0.79) +ve
55 Lidocaine for preventing postoperative sore
throat
RR 0.64 (0.48, 0.85) +ve
56 Early versus delayed initiation of continuous
distending pressure for respiratory distress
RR 0.55 (0.32, 0.96) +ve
Continued on next page
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Table 1 – continued from previous page
Study Study Title Statistic Used
Number and effect direction
57 Pre-operative radiotherapy and curative
surgery for the management of localized rectal
carcinoma
OR 0.93 (0.87, 1.00) +ve
58 Fibrin glue instillation under skin flaps to
prevent seroma-related morbidity following
breast
RR 1.02 (0.90, 1.16) -ve
59 Brief co-incubation of sperm and oocytes for in
vitro fertilization techniques
OR 2.42 (1.55, 3.77) +ve
60 Sodium bicarbonate infusion during
resuscitation of infants at birth
RR 1.04 (0.49,2.21) +ve
61 High feedback versus low feedback of prenatal
ultrasound for reducing maternal anxiety
RR 3.30 (0.73, 14.85) +ve
62 Propranolol for migraine prophylaxis RR 1.72 (1.23, 2.40) +ve
63 Bispectral index for improving anaesthetic
delivery and postoperative recovery
OR 0.24 (0.12, 0.48) +ve
64 Vitamin K antagonists versus antiplatelet
therapy after transient ischaemic attack
RR 0.80 (0.56, 1.14) +ve
65 Motivational interviewing for improving
outcomes in youth living with HIV
OR 1.23 (0.57, 2.63) -ve
66 Substitution of doctors by nurses in primary
care
RR 1.02 (0.98, 1.05) -ve
67 Regular treatment with salmeterol and inhaled
steroids for chronic asthma: serious adverse
events
OR 0.90 (0.31, 2.60) -ve
68 Isotonic versus hypotonic solutions for
maintenance intravenous fluid administration
in children
RR 0.48 (0.38, 0.60) +ve
69 Intermittent pneumatic compression for treating
venous leg ulcers
RR 2.27 (1.30, 3.97) +ve
70 Intravenous oxytocin alone for cervical ripening
and induction of labour
RR 0.16 (0.10, 0.25) +ve
71 Topical NSAIDs for chronic musculoskeletal
pain in adults
RR 1.17 (1.08, 1.26) +ve
72 Endoscopic third ventriculostomy (ETV) for
idiopathic normal pressure hydrocephalus
(iNPH)
OR 1.12 (0.26, 4.76) +ve
73 Interventions for preventing falls in people after
stroke
R1 0.92 (0.45, 1.90) +ve
Continued on next page
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Table 1 – continued from previous page
Study Study Title Statistic Used
Number and effect direction
74 Antioxidant supplements for preventing
gastrointestinal cancers
RR 0.94 (0.83 1.06) +ve
75 Mucolytic agents for chronic bronchitis or
chronic obstructive pulmonary disease
OR 1.75 (1.57, 1.94) +ve
76 Interventions for preventing infection in
nephrotic syndrome
RR 0.47 (0.31,0.73) +ve
77 Hydration for treatment of preterm labour RR 1.09 (0.71,1.68) -ve
78 Grey literature in meta-analyses of randomized
trials of health care interventions
R2 1.09 (1.03, 1.16) +ve
79 Heparin versus 0.9% sodium chloride
intermittent flushing for prevention of occlusion
in central venous
RR 0.53 (0.29, 0.94) +ve
80 Herbal medicines for fatty liver diseases RR 0.36 (0.14, 0.97) +ve
81 Patient education for preventing diabetic foot
ulceration
RR 0.31 (0.14, 0.65) +ve
82 Budesonide versus placebo for chronic asthma
in children and adults
RR 0.17 (0.09, 0.33) +ve
83 Combined use of hyperthermia and radiation
therapy for treating locally advanced cervix
carcinoma
RR 0.56 (0.39, 0.79) +ve
84 Active cycle of breathing technique for cystic
fibrosis
RR 1.64 (0.62, 4.34) +ve
85 Opioid antagonists for smoking cessation RR 1.00 (0.66, 1.51) +/-
86 Ergonomic design and training for preventing
work-related musculoskeletal disorders of the
upper limb
RR 0.52 (0.27, 0.99) +ve
87 Antibiotics prior to embryo transfer in ART OR 1.02 (0.66, 1.58) -ve
88 Vaccines for preventing smallpox RR 0.97 (0.90, 1.03) +ve
89 Testosterone for schizophrenia RR 0.23 (0.09, 0.57) +ve
90 Optimal monitoring strategies for guiding
when to switch first-line antiretroviral therapy
regimens
HR 1.35 (1.12, 1.63) +ve
91 Excisional surgery versus ablative surgery for
ovarian endometriomata
OR 0.15 (0.06, 0.38) +ve
92 Enteral nutrition formulations for acute
pancreatitis
RR 0.49 (0.29, 0.80) +ve
93 Colchicine for acute gout RR 2.16 (1.28, 3.65) +ve
Continued on next page
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Table 1 – continued from previous page
Study Study Title Statistic Used
Number and effect direction
94 Tricyclic antidepressants for attention deficit
hyperactivity disorder (ADHD) in children and
adolescents
OR 18.50 (6.29, 54.39) +ve
95 Artificial and bioartificial support systems for
liver failure
RR 0.86 (0.65, 1.14) +ve
96 Slum upgrading strategies involving physical
environment and infrastructure interventions
RR 0.53 (0.27, 1.04) +ve
97 Biocompatible hemodialysis membranes for
acute renal failure
RR 0.93 (0.81, 1.07) +ve
98 Cognitive behavioural therapy for men who
physically abuse their female partner
RR 0.86 (0.54, 1.38) +ve
99 Abdominal drainage to prevent intra-peritoneal
abscess after open appendectomy
RR 1.23 (0.47, 3.21) -ve
100 Lidocaine for reducing propofol -induced pain
on induction of anaesthesia in adults
OR 0.19 (0.15,0.25) +ve
Notes RR - relative risk
OR - Odds Ratio
HR - Hazard Ratio
R1 - rate ratio
R2 - ratio of Odds ratios
Table 2. Results for each study
Abbreviated Column Headings*
# RR Orig Dirn Prob CCI E(RR) Dirn Rank
95% Expctd Effect Expctd
conf int < 0 =0 > 0
1 1.24 ( 1.06, 1.44) Yes 0.00 0.07 0.93 [ 1.00, 1.41) 1.24 Yes 3
2 0.88 ( 0.36, 2.16) Yes 0.05 0.41 0.54 ( 0.48, 1.11) 0.81 Yes 4
3 0.79 ( 0.43, 1.47) Yes 0.04 0.38 0.58 ( 0.51, 1.06) 0.81 Yes 3
4 0.02 ( 0.01, 0.09) Yes 0.00 0.00 1.00 ( 0.12, 0.84) 0.26 Yes 4
5 0.84 ( 0.57, 1.25) Yes 0.04 0.44 0.53 ( 0.60, 1.03) 0.86 Yes 2
6 2.04 ( 0.75, 5.54) Yes 0.02 0.22 0.76 ( 0.98, 2.73) 1.51 Yes 2
7 0.71 ( 0.56, 0.89) Yes 0.00 0.03 0.97 ( 0.55, 0.91) 0.71 Yes 4
8 0.49 ( 0.41, 0.58) Yes 0.00 0.00 1.00 ( 0.42, 0.62) 0.51 Yes 5
9 1.13 ( 0.71, 1.77) Yes 0.05 0.48 0.47 ( 0.94, 1.66) 1.14 Yes 3
10 0.67 ( 0.56, 0.79) Yes 0.00 0.00 1.00 ( 0.57, 0.80) 0.67 Yes 4
Continued on next page
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Abbreviated Column Headings*
# RR Orig Dirn Prob CCI E(RR) Dirn Rank
95% Expctd Effect Expctd
conf int < 0 =0 > 0
11 0.30 ( 0.09, 0.94) Yes 0.02 0.14 0.84 ( 0.31, 1.00] 0.58 Yes 4
12 0.74 ( 0.58, 0.95) Yes 0.00 0.10 0.90 ( 0.61, 1.00] 0.75 Yes 4
13 1.03 ( 0.87, 1.22) No 0.10 0.76 0.14 ( 0.88, 1.09) 0.99 Yes 3
14 1.00 ( 0.74, 1.36) +/- 0.08 0.64 0.28 ( 0.75, 1.09) 0.96 Yes 2
15 0.66 ( 0.44, 0.98) Yes 0.01 0.13 0.87 ( 0.50, 1.00] 0.70 Yes 4
16 0.23 ( 0.09, 0.57) Yes 0.00 0.03 0.97 ( 0.23, 0.95) 0.48 Yes 5
17 0.37 ( 0.26, 0.51) Yes 0.00 0.00 1.00 ( 0.31, 0.68) 0.44 Yes 5
18 0.71 ( 0.54, 0.95) Yes 0.00 0.09 0.91 ( 0.57, 1.00] 0.72 Yes 5
19 0.23 ( 0.05, 1.01) Yes 0.02 0.17 0.81 ( 0.31, 1.02) 0.60 Yes 3
20 0.40 ( 0.20, 0.78) Yes 0.00 0.04 0.95 ( 0.34, 1.00] 0.54 Yes 4
21 3.18 ( 1.03, 9.79) Yes 0.01 0.14 0.85 [ 1.00, 3.16) 1.72 Yes 3
22 1.04 ( 0.64, 1.69) No 0.08 0.57 0.35 ( 0.66, 1.14) 0.93 Yes 4
23 1.02 ( 0.96, 1.08) Yes 0.03 0.84 0.13 [ 1.00, 1.06) 1.00 Yes 3
24 0.51 ( 0.21, 1.23) Yes 0.02 0.20 0.78 ( 0.37, 1.00] 0.66 Yes 5
25 0.75 ( 0.19, 2.90) No 0.07 0.43 0.49 ( 0.84, 2.10) 1.20 Yes 3
26 0.79 ( 0.55, 1.13) Yes 0.02 0.35 0.63 ( 0.59, 1.00] 0.83 Yes 4
27 0.69 ( 0.55, 0.87) Yes 0.00 0.01 0.99 ( 0.55, 0.87) 0.69 Yes 5
28 1.40 ( 0.72, 2.70) No 0.13 0.58 0.29 ( 0.66, 1.27) 0.95 Yes 3
29 0.52 ( 0.25, 1.05) Yes 0.01 0.15 0.84 ( 0.39, 1.00] 0.64 Yes 4
30 0.77 ( 0.35, 1.72) Yes 0.04 0.36 0.59 ( 0.47, 1.07) 0.79 Yes 4
31 1.18 ( 1.12, 1.25) Yes 0.00 0.00 1.00 ( 1.12, 1.25) 1.18 Yes 4
32 0.85 ( 0.22, 3.26) Yes 0.05 0.37 0.58 ( 0.43, 1.13) 0.77 Yes 4
33 3.01 ( 0.92, 9.81) No 0.14 0.54 0.32 ( 0.60, 1.36) 0.94 Yes 2
34 0.75 ( 0.51, 1.11) Yes 0.02 0.28 0.70 ( 0.56, 1.00] 0.79 Yes 1
35 0.63 ( 0.47, 0.86) Yes 0.00 0.02 0.98 ( 0.48, 0.87) 0.65 Yes 1
36 0.27 ( 0.18, 0.42) Yes 0.00 0.00 1.00 ( 0.24, 0.68) 0.37 Yes 5
37 1.57 ( 0.22,11.08) No 0.07 0.40 0.53 ( 0.44, 1.18) 0.80 Yes 4
38 0.97 ( 0.67, 1.42) Yes 0.07 0.58 0.35 ( 0.69, 1.09) 0.93 Yes 4
39 1.49 ( 1.04, 2.14) Yes 0.00 0.11 0.89 [ 1.00, 1.92) 1.43 Yes 4
40 0.77 ( 0.62, 0.95) Yes 0.00 0.11 0.88 ( 0.65, 1.00] 0.78 Yes 5
41 1.42 ( 1.19, 1.69) Yes 0.00 0.00 1.00 ( 1.20, 1.68) 1.42 Yes 5
42 0.84 ( 0.73, 0.97) Yes 0.00 0.17 0.83 ( 0.74, 1.00] 0.85 Yes 5
43 0.93 ( 0.58, 1.50) Yes 0.06 0.51 0.43 ( 0.62, 1.09) 0.90 Yes 3
44 0.76 ( 0.44, 1.32) No 0.14 0.60 0.26 ( 0.79, 1.42) 1.03 Yes 3
45 0.28 ( 0.09, 0.86) Yes 0.01 0.11 0.87 ( 0.31, 1.00] 0.56 Yes 2
46 0.48 ( 0.25, 0.92) Yes 0.01 0.08 0.91 ( 0.38, 1.00] 0.59 Yes 3
47 1.45 ( 0.64, 3.27) No 0.11 0.54 0.35 ( 0.61, 1.25) 0.92 Yes 3
Continued on next page
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Abbreviated Column Headings*
# RR Orig Dirn Prob CCI E(RR) Dirn Rank
95% Expctd Effect Expctd
conf int < 0 =0 > 0
48 0.48 ( 0.28, 0.84) Yes 0.00 0.04 0.96 ( 0.31, 0.97) 0.57 Yes 5
49 0.85 ( 0.18, 4.00) Yes 0.05 0.36 0.58 ( 0.42, 1.14) 0.77 Yes 3
50 1.00 ( 0.08,13.02) +/- 0.06 0.36 0.58 ( 0.40, 1.15) 0.75 Yes 4
51 1.19 ( 0.99, 1.43) Yes 0.01 0.31 0.68 [ 1.00, 1.39) 1.15 Yes 4
52 0.30 ( 0.14, 0.63) Yes 0.00 0.02 0.98 ( 0.26, 0.90) 0.48 Yes 5
53 0.85 ( 0.18, 4.05) Yes 0.05 0.36 0.58 ( 0.42, 1.14) 0.77 Yes 3
54 0.69 ( 0.61, 0.79) Yes 0.00 0.00 1.00 ( 0.61, 0.79) 0.69 Yes 4
55 0.64 ( 0.48, 0.85) Yes 0.00 0.01 0.98 ( 0.49, 0.86) 0.65 Yes 4
56 0.55 ( 0.32, 0.96) Yes 0.01 0.09 0.90 ( 0.42, 1.00] 0.63 Yes 5
57 0.93 ( 0.87, 1.00) Yes 0.01 0.49 0.51 ( 0.88, 1.00] 0.96 Yes 5
58 1.02 ( 0.90, 1.16) No 0.09 0.80 0.11 ( 0.92, 1.06) 1.00 Yes 3
59 2.42 ( 1.55, 3.77) Yes 0.00 0.00 1.00 ( 1.26, 3.01) 2.02 Yes 5
60 1.04 ( 0.49, 2.21) No 0.07 0.48 0.44 ( 0.55, 1.15) 0.87 Yes 3
61 2.93 ( 1.25, 6.86) Yes 0.01 0.07 0.93 [ 1.00, 3.12) 1.86 Yes 3
62 1.72 ( 1.23, 2.40) Yes 0.00 0.01 0.99 ( 1.19, 2.25) 1.64 Yes 5
63 0.24 ( 0.12, 0.48) Yes 0.00 0.00 1.00 ( 0.25, 0.83) 0.42 Yes 5
64 0.80 ( 0.56, 1.14) Yes 0.02 0.36 0.61 ( 0.59, 1.00] 0.84 Yes 1
65 1.23 ( 0.57, 2.63) No 0.09 0.53 0.38 ( 0.59, 1.20) 0.91 Yes 5
66 1.02 ( 0.98, 1.05) No 0.10 0.88 0.02 [ 1.00, 1.03) 1.00 No 3
67 0.90 ( 0.31, 2.60) No 0.07 0.44 0.49 ( 0.86, 2.02) 1.19 Yes 3
68 0.48 ( 0.38, 0.60) Yes 0.00 0.00 1.00 ( 0.40, 0.67) 0.51 Yes 5
69 2.27 ( 1.30, 3.97) Yes 0.00 0.02 0.98 ( 1.12, 3.09) 1.85 Yes 4
70 0.16 ( 0.10, 0.25) Yes 0.00 0.00 1.00 ( 0.16, 0.63) 0.28 Yes 5
71 1.17 ( 1.08, 1.26) Yes 0.00 0.00 1.00 ( 1.09, 1.27) 1.18 Yes 5
72 1.12 ( 0.26, 4.76) Yes 0.06 0.37 0.57 ( 0.88, 2.35) 1.29 Yes 3
73 0.92 ( 0.45, 1.90) Yes 0.06 0.45 0.49 ( 0.53, 1.11) 0.85 Yes 3
74 0.94 ( 0.83, 1.06) Yes 0.03 0.68 0.29 ( 0.84, 1.00] 0.97 Yes 2
75 1.75 ( 1.57, 1.94) Yes 0.00 0.00 1.00 ( 1.55, 1.94) 1.73 Yes 4
76 0.47 ( 0.31, 0.73) Yes 0.00 0.00 1.00 ( 0.37, 0.83) 0.54 Yes 4
77 1.09 ( 0.71, 1.68) No 0.10 0.61 0.29 ( 0.71, 1.16) 0.96 Yes 3
78 1.09 ( 1.03, 1.16) Yes 0.00 0.17 0.83 [ 1.00, 1.15) 1.08 Yes 5
79 0.53 ( 0.29, 0.94) Yes 0.01 0.10 0.90 ( 0.41, 1.00] 0.62 Yes 3
80 0.36 ( 0.14, 0.97) Yes 0.01 0.12 0.87 ( 0.33, 1.00] 0.58 Yes 4
81 0.31 ( 0.14, 0.66) Yes 0.00 0.03 0.97 ( 0.26, 0.93) 0.50 Yes 4
82 0.17 ( 0.09, 0.33) Yes 0.00 0.00 1.00 ( 0.20, 0.77) 0.35 Yes 5
83 0.56 ( 0.39, 0.79) Yes 0.00 0.01 0.99 ( 0.43, 0.84) 0.59 Yes 4
84 1.64 ( 0.62, 4.34) Yes 0.03 0.29 0.68 ( 0.95, 2.48) 1.40 Yes 1
Continued on next page
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Table 2 – continued from previous page
Abbreviated Column Headings*
# RR Orig Dirn Prob CCI E(RR) Dirn Rank
95% Expctd Effect Expctd
conf int < 0 =0 > 0
85 1.00 ( 0.66, 1.51) +/- 0.08 0.58 0.34 ( 0.68, 1.11) 0.94 Yes 1
86 0.52 ( 0.27, 0.99) Yes 0.01 0.12 0.87 ( 0.40, 1.00] 0.62 Yes 4
87 1.02 ( 0.66, 1.58) No 0.08 0.58 0.34 ( 0.68, 1.13) 0.94 Yes 2
88 0.97 ( 0.90, 1.03) Yes 0.03 0.80 0.17 ( 0.93, 1.00] 0.99 Yes 3
89 0.23 ( 0.09, 0.57) Yes 0.00 0.03 0.97 ( 0.23, 0.95) 0.48 Yes 3
90 1.35 ( 1.12, 1.63) Yes 0.00 0.02 0.98 ( 1.12, 1.65) 1.35 Yes 5
91 0.15 ( 0.06, 0.38) Yes 0.00 0.01 0.99 ( 0.21, 0.86) 0.41 Yes 5
92 0.49 ( 0.29, 0.80) Yes 0.00 0.03 0.97 ( 0.34, 0.91) 0.57 Yes 4
93 2.16 ( 1.28, 3.65) Yes 0.00 0.02 0.98 ( 1.12, 2.96) 1.82 Yes 5
94 18.50 ( 6.29,54.39) Yes 0.00 0.00 1.00 ( 1.19, 6.06) 2.95 Yes 5
95 0.86 ( 0.65, 1.14) Yes 0.03 0.47 0.50 ( 0.67, 1.01) 0.89 Yes 4
96 0.53 ( 0.27, 1.04) Yes 0.01 0.14 0.85 ( 0.40, 1.00] 0.64 Yes 4
97 0.93 ( 0.81, 1.07) Yes 0.03 0.65 0.33 ( 0.82, 1.00] 0.96 Yes 1
98 0.86 ( 0.54, 1.38) Yes 0.04 0.45 0.50 ( 0.59, 1.06) 0.86 Yes 3
99 1.23 ( 0.47, 3.21) No 0.08 0.48 0.44 ( 0.53, 1.19) 0.87 Yes 3
100 0.19 ( 0.15, 0.25) Yes 0.00 0.00 1.00 ( 0.17, 0.43) 0.24 Yes 5
*Table Heading Explanations
RR Relative Risk
Orig 95% conf int Original 95% confidence interval
Dirn Expctd “Does the RR tend in the anticipated direction?”
Prob Effect < 0 Probability the treatment effect is opposite to that anticipated
Prob Effect = 0 Probability there is no treatment effect ie. RR=1.00
Prob Effect > 0 Probability the treatment effect is in direction anticipated
CCI Contracted Confidence Interval. Also note:-
The square bracket “ [ ”or “ ] ” includes the 1.00 endpoint in the confidence interval
E(RR) The expected value of the relative risk
Dirn Expctd “Does the E(RR) tend in the anticipated direction?”
Rank The effectiveness ranking interpreted from the Cochrane summary
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